New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

If approved, apitegromab could soon face competition from other myostatin inhibitors in late-stage development, including Biohaven’s taldefgrobep alfa and Roche’s GYM329 (also known as RO7204239).

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Research suggests that the peptide may function as a competitive antagonist to myostatin, thereby impacting muscle cell proliferation. Research indicates that Follistatin-344 may interact with activin ...

Nicotinic acetylcholine (ACh) receptors and other Cys-loop receptors challenge our ability to understand how proteins carry out simple sets of functions — in this case, specific binding ...

What new targets will iBio announce during the call? iBio will announce a third target in the AstralBio Collaboration, alongside Myostatin and Activin E. Where can I find the webcast of the call?

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...